Locomotor stimulation produced by 3,4-methylenedioxymethamphetamine (MDMA) is correlated with dialysate levels of serotonin and dopamine in rat brain

Pharmacology Biochemistry and Behavior

Volumn 90, Issue 2, 2008, Pages 208-217

  Baumann, Michael H ^a   Clark, Robert D ^a   Rothman, Richard B ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Ambulation; Dopamine; MDMA; Microdialysis; Serotonin; Stereotypy

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; DOPAMINE; SEROTONIN;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; BRAIN REGION; CONTROLLED STUDY; CORPUS STRIATUM; DIALYSATE LEVEL; DOPAMINE BRAIN LEVEL; DOPAMINE RELEASE; DOSE RESPONSE; DRUG EFFECT; FOREFOOT; HEAD MOVEMENT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIGHT; LOCOMOTION; MALE; MICRODIALYSIS; MOBILIZATION; MOTOR ACTIVITY; NEUROCHEMISTRY; NEUROTRANSMITTER RELEASE; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; SEROTONIN BRAIN LEVEL; SEROTONIN RELEASE; STATISTICAL SIGNIFICANCE; STEREOTYPY;

ANIMALS; CORPUS STRIATUM; DOPAMINE; MALE; MICRODIALYSIS; MOTOR ACTIVITY; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT2C; SEROTONIN;

RATTUS;

EID: 44649093192     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2008.02.018     Document Type: Article

References (100)

1. Alex K.D., and Pehek E.A. Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol Ther 113 (2007) 296-320
2. Amalric M., and Koob G.F. Functionally selective neurochemical afferents and efferents of the mesocorticolimbic and nigrostriatal dopamine system. Prog Brain Res 99 (1993) 209-226
3. Andrews C.D., Fernando J.C., and Curzon G. Differential involvement of dopamine-containing tracts in 5-hydroxytryptamine-dependent behaviours caused by amphetamine in large doses. Neuropharmacology 21 (1982) 63-68
4. Ball K.T., Budreau D., and Rebec G.V. Acute effects of 3,4-methylenedioxymethamphetamine on striatal single-unit activity and behavior in freely moving rats: differential involvement of dopamine D(1) and D(2) receptors. Brain Res 994 (2003) 203-215
5. Ball K.T., and Rebec G.V. Role of 5-HT2A and 5-HT2C/B receptors in the acute effects of 3,4-methylenedioxymethamphetamine (MDMA) on striatal single-unit activity and locomotion in freely moving rats. Psychopharmacology (Berl) 181 (2005) 676-687
6. Bankson M.G., and Cunningham K.A. 3,4-Methylenedioxymethamphetamine (MDMA) as a unique model of serotonin receptor function and serotonin-dopamine interactions. J Pharmacol Exp Ther 297 (2001) 846-852
7. Bankson M.G., and Cunningham K.A. Pharmacological studies of the acute effects of (+)-3,4-methylenedioxymethamphetamine on locomotor activity: role of 5-HT(1B/1D) and 5-HT(2) receptors. Neuropsychopharmacology 26 (2002) 40-52
8. Barnes N.M., and Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology 38 (1999) 1083-1152
9. Baumann M.H., Ayestas M.A., Dersch C.M., Brockington A., Rice K.C., and Rothman R.B. Effects of phentermine and fenfluramine on extracellular dopamine and serotonin in rat nucleus accumbens: therapeutic implications. Synapse 36 (2000) 102-113
10. Baumann M.H., Ayestas M.A., Dersch C.M., and Rothman R.B. 1-(m-chlorophenyl)piperazine (mCPP) dissociates in vivo serotonin release from long-term serotonin depletion in rat brain. Neuropsychopharmacology 24 (2001) 492-501
11. Baumann M.H., Ayestas M.A., Rothman R.B.,. Functional consequences of central serotonin depletion produced by repeated fenfluramine administration in rats. J Neurosci 18 (1998) 9069-9077
12. Baumann M.H., Clark R.D., Budzynski A.G., Partilla J.S., Blough B.E., and Rothman R.B. N-substituted piperazines abused by humans mimic the molecular mechanism of 3,4-methylenedioxymethamphetamine (MDMA, or 'Ecstasy'). Neuropsychopharmacology 30 (2005) 550-560
13. Baumann M.H., and Rutter J.J. Application of in vivo microdialysis methods to the study of psychomotor stimulant drugs. In: Waterhouse B. (Ed). Methods in Drug Abuse Research: Cellular and Circuit Level Analyses (2003), CRC Press, Boca Raton 51-86
14. Baumann M.H., Wang X., and Rothman R.B. 3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings. Psychopharmacology (Berl) 189 (2007) 407-424
15. Bengel D., Murphy D.L., Andrews A.M., Wichems C.H., Feltner D., Heils A., et al. Altered brain serotonin homeostasis and locomotor insensitivity to 3, 4-methylenedioxymethamphetamine ("Ecstasy") in serotonin transporter-deficient mice. Mol. Pharmacol. 53 (1998) 649-655
16. Blanc G., Trovero F., Vezina P., Herve D., Godeheu A.M., Glowinski J., et al. Blockade of prefronto-cortical alpha 1-adrenergic receptors prevents locomotor hyperactivity induced by subcortical d-amphetamine injection. Eur. J. Neurosci. 6 (1994) 293-298
17. Bubar M.J., and Cunningham K.A. Serotonin 5-HT2A and 5-HT2C receptors as potential targets for modulation of psychostimulant use and dependence. Curr Top Med Chem 6 (2006) 1971-1985
18. Bubar M.J., Pack K.M., Frankel P.S., and Cunningham K.A. Effects of dopamine D1- or D2-like receptor antagonists on the hypermotive and discriminative stimulus effects of (+)-MDMA. Psychopharmacology (Berl) 173 (2004) 326-336
19. Bubser M., Backstrom J.R., Sanders-Bush E., Roth B.L., and Deutch A.Y. Distribution of serotonin 5-HT(2A) receptors in afferents of the rat striatum. Synapse 39 (2001) 297-304
20. Callaway C.W., and Geyer M.A. Stimulant effects of 3,4-methylenedioxymethamphetamine in the nucleus accumbens of rat. Eur J Pharmacol 214 (1992) 45-51
21. Callaway C.W., and Geyer M.A. Tolerance and cross-tolerance to the activating effects of 3,4-methylenedioxymethamphetamine and a 5-hydroxytryptamine1B agonist. J Pharmacol Exp Ther 263 (1992) 318-326
22. Callaway C.W., Johnson M.P., Gold L.H., Nichols D.E., and Geyer M.A. Amphetamine derivatives induce locomotor hyperactivity by acting as indirect serotonin agonists. Psychopharmacology (Berl) 104 (1991) 293-301
23. Callaway C.W., Wing L.L., and Geyer M.A. Serotonin release contributes to the locomotor stimulant effects of 3,4-methylenedioxymethamphetamine in rats. J Pharmacol Exp Ther 254 (1990) 456-464
24. Cole J.C., Bailey M., Sumnall H.R., Wagstaff G.F., and King L.A. The content of ecstasy tablets: implications for the study of their long-term effects. Addiction 97 (2002) 1531-1536
25. Creese I., and Iversen S.D. The role of forebrain dopamine systems in amphetamine induced stereotyped behavior in the rat. Psychopharmacologia 39 (1974) 345-357
26. Crespi D., Mennini T., and Gobbi M. Carrier-dependent and Ca(2+)-dependent 5-HT and dopamine release induced by (+)-amphetamine, 3,4-methylendioxymethamphetamine, p-chloroamphetamine and (+)-fenfluramine. Br J Pharmacol 121 (1997) 1735-1743
27. Darracq L., Blanc G., Glowinski J., and Tassin J.P. Importance of the noradrenaline-dopamine coupling in the locomotor activating effects of d-amphetamine. J Neurosci 18 (1998) 2729-2739
28. de la Torre R., and Farre M. Neurotoxicity of MDMA (ecstasy): the limitations of scaling from animals to humans. Trends Pharmacol Sci 25 (2004) 505-508
29. Di Matteo V., De Blasi A., Di Giulio C., and Esposito E. Role of 5-HT(2C) receptors in the control of central dopamine function. Trends Pharmacol Sci 22 (2001) 229-232
30. Di Matteo V., Di Giovanni G., Di Mascio M., and Esposito E. Biochemical and electrophysiological evidence that RO 60-0175 inhibits mesolimbic dopaminergic function through serotonin(2C) receptors. Brain Res 865 (2000) 85-90
31. Fletcher P.J., Korth K.M., Robinson S.R., and Baker G.B. Multiple 5-HT receptors are involved in the effects of acute MDMA treatment: studies on locomotor activity and responding for conditioned reinforcement. Psychopharmacology (Berl) 162 (2002) 282-291
32. Fletcher P.J., Sinyard J., and Higgins G.A. The effects of the 5-HT(2C) receptor antagonist SB242084 on locomotor activity induced by selective, or mixed, indirect serotonergic and dopaminergic agonists. Psychopharmacology (Berl) 187 (2006) 515-525
33. Geyer M.A. Serotonergic functions in arousal and motor activity. Behav Brain Res 73 (1996) 31-35
34. Gobert A., and Millan M.J. Serotonin (5-HT)2A receptor activation enhances dialysate levels of dopamine and noradrenaline, but not 5-HT, in the frontal cortex of freely-moving rats. Neuropharmacology 38 (1999) 315-317
35. Gold L.H., Geyer M.A., and Koob G.F. Neurochemical mechanisms involved in behavioral effects of amphetamines and related designer drugs. NIDA Res Monogr 94 (1989) 101-126
36. Gold L.H., Hubner C.B., and Koob G.F. A role for the mesolimbic dopamine system in the psychostimulant actions of MDMA. Psychopharmacology (Berl) 99 (1989) 40-47
37. Gold L.H., Koob G.F., and Geyer M.A. Stimulant and hallucinogenic behavioral profiles of 3,4-methylenedioxymethamphetamine and N-ethyl-3,4-methylenedioxyamphetamine in rats. J Pharmacol Exp Ther 247 (1988) 547-555
38. Gough B., Imam S.Z., Blough B., Slikker Jr. W., and Ali S.F. Comparative effects of substituted amphetamines (PMA, MDMA, and sMETH) on monoamines in rat caudate: a microdialysis study. Ann N Y Acad Sci 965 (2002) 410-420
39. Gouzoulis-Mayfrank E., and Daumann J. Neurotoxicity of methylenedioxyamphetamines (MDMA; ecstasy) in humans: how strong is the evidence for persistent brain damage?. Addiction 101 (2006) 348-361
40. Green A.R. 5-HT-mediated behavior. Animal studies. Neuropharmacology 23 (1984) 1521-1528
41. Green A.R., Mechan A.O., Elliott J.M., O'Shea E., and Colado M.I. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol Rev 55 (2003) 463-508
42. Grillner S., Hellgren J., Menard A., Saitoh K., and Wikstrom M.A. Mechanisms for selection of basic motor programs-roles for the striatum and pallidum. Trends Neurosci 28 (2005) 364-370
43. Gudelsky G.A., and Nash J.F. Carrier-mediated release of serotonin by 3,4-methylenedioxymethamphetamine: implications for serotonin-dopamine interactions. J Neurochem 66 (1996) 243-249
44. Harris D.S., Baggott M., Mendelson J.H., Mendelson J.E., and Jones R.T. Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology (Berl) 162 (2002) 396-405
45. Hilber B., Scholze P., Dorostkar M.M., Sandtner W., Holy M., Boehm S., et al. Serotonin-transporter mediated efflux: a pharmacological analysis of amphetamines and non-amphetamines. Neuropharmacology 49 (2005) 811-819
46. Hillegaart V., Magnusson O., and Ahlenius S. A9 and A10 dopamine nuclei as a site of action for effects of 8-OH-DPAT on locomotion in the rat. Pharmacol Biochem Behav 67 (2000) 55-63
47. Hiramatsu M., Nabeshima T., Kameyama T., Maeda Y., and Cho A.K. The effect of optical isomers of 3,4-methylenedioxymethamphetamine (MDMA) on stereotyped behavior in rats. Pharmacol Biochem Behav 33 (1989) 343-347
48. Hoyer D., Hannon J.P., and Martin G.R. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 71 (2002) 533-554
49. Ikemoto S. Ventral striatal anatomy of locomotor activity induced by cocaine, d-amphetamine, dopamine and D1/D2 agonists. Neuroscience 113 (2002) 939-955
50. Jacobs B.L. An animal behavior model for studying central serotonergic synapses. Life Sci 19 (1976) 777-785
51. Johnson M.P., Hoffman A.J., and Nichols D.E. Effects of the enantiomers of MDA, MDMA and related analogues on [3H]serotonin and [3H]dopamine release from superfused rat brain slices. Eur J Pharmacol 132 (1986) 269-276
52. Kankaanpaa A., Meririnne E., Lillsunde P., and Seppala T. The acute effects of amphetamine derivatives on extracellular serotonin and dopamine levels in rat nucleus accumbens. Pharmacol Biochem Behav 59 (1998) 1003-1009
53. Kehne J.H., Ketteler H.J., McCloskey T.C., Sullivan C.K., Dudley M.W., and Schmidt C.J. Effects of the selective 5-HT2A receptor antagonist MDL 100,907 on MDMA-induced locomotor stimulation in rats. Neuropsychopharmacology 15 (1996) 116-124
54. Kelly P.H., Seviour P.W., and Iversen S.D. Amphetamine and apomorphine responses in the rat following 6-OHDA lesions of the nucleus accumbens septi and corpus striatum. Brain Res 94 (1975) 507-522
55. Kuczenski R., and Segal D. Concomitant characterization of behavioral and striatal neurotransmitter response to amphetamine using in vivo microdialysis. J Neurosci 9 (1989) 2051-2065
56. Kuczenski R., Segal D.S., Cho A.K., and Melega W. Hippocampus norepinephrine, caudate dopamine and serotonin, and behavioral responses to the stereoisomers of amphetamine and methamphetamine. J Neurosci 15 (1995) 1308-1317
57. Liechti M.E., and Vollenweider F.X. Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies. Hum Psychopharmacol 16 (2001) 589-598
58. Lopez-Gimenez J.F., Mengod G., Palacios J.M., and Vilaro M.T. Selective visualization of rat brain 5-HT2A receptors by autoradiography with [3H]MDL 100,907. Naunyn Schmiedebergs Arch Pharmacol 356 (1997) 446-454
59. Lucas G., and Spampinato U. Role of striatal serotonin2A and serotonin2C receptor subtypes in the control of in vivo dopamine outflow in the rat striatum. J Neurochem 74 (2000) 693-701
60. Ludwig V., and Schwarting R.K. Neurochemical and behavioral consequences of striatal injection of 5,7-dihydroxytryptamine. J Neurosci Methods 162 (2007) 108-118
61. McCann U.D., Eligulashvili V., and Ricaurte G.A. (+/-)3,4-Methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: clinical studies. Neuropsychobiology 42 (2000) 11-16
62. McCreary A.C., Bankson M.G., and Cunningham K.A. Pharmacological studies of the acute and chronic effects of (+)-3, 4-methylenedioxymethamphetamine on locomotor activity: role of 5-hydroxytryptamine(1A) and 5-hydroxytryptamine(1B/1D) receptors. J Pharmacol Exp Ther 290 (1999) 965-973
63. McCreary A.C., and Cunningham K.A. Effects of the 5-HT2C/2B antagonist SB 206553 on hyperactivity induced by cocaine. Neuropsychopharmacology 20 (1999) 556-564
64. Mechan A.O., Esteban B., O'Shea E., Elliott J.M., Colado M.I., and Green A.R. The pharmacology of the acute hyperthermic response that follows administration of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') to rats. Br J Pharmacol 135 (2002) 170-180
65. Mogenson G.J., Jones D.L., and Yim C.Y. From motivation to action: functional interface between the limbic system and the motor system. Prog Neurobiol 14 (1980) 69-97
66. Moore R.Y., and Bloom F.E. Central catecholamine neuron systems: anatomy and physiology of the dopamine systems. Annu Rev Neurosci 1 (1978) 129-169
67. Morley K.C., Arnold J.C., and McGregor I.A. Serotonin (1A) receptor involvement in acute 3,4-methylenedioxymethamphetamine (MDMA) facilitation of social interaction in the rat. Prog Neuropsychopharmacol Biol Psychiatry 29 (2005) 648-667
68. Olive M.F., Mehmert K.K., and Hodge C.W. Microdialysis in the mouse nucleus accumbens: a method for detection of monoamine and amino acid neurotransmitters with simultaneous assessment of locomotor activity. Brain Res Brain Res Protoc 5 (2000) 16-24
69. Pan H.S., and Wang R.Y. The action of (+/-)-MDMA on medial prefrontal cortical neurons is mediated through the serotonergic system. Brain Res 543 (1991) 56-60
70. Pan H.S., and Wang R.Y. MDMA: further evidence that its action in the medial prefrontal cortex is mediated by the serotonergic system. Brain Res 539 (1991) 332-336
71. Paulus M.P., and Geyer M.A. The effects of MDMA and other methylenedioxy-substituted phenylalkylamines on the structure of rat locomotor activity. Neuropsychopharmacology 7 (1992) 15-31
72. Paxinos G., and Watson C. The rat brain in stereotaxic coordinates (2005), Elsevier, New York
73. Pehek E.A., McFarlane H.G., Maguschak K., Price B., and Pluto C.P. M100,907, a selective 5-HT(2A) antagonist, attenuates dopamine release in the rat medial prefrontal cortex. Brain Res 888 (2001) 51-59
74. Pennartz C.M., Groenewegen H.J., and Lopes da Silva F.H. The nucleus accumbens as a complex of functionally distinct neuronal ensembles: an integration of behavioural, electrophysiological and anatomical data. Prog Neurobiol 42 (1994) 719-761
75. Pijnenburg A.J., Honig W.M., Van der Heyden J.A., and Van Rossum J.M. Effects of chemical stimulation of the mesolimbic dopamine system upon locomotor activity. Eur J Pharmacol 35 (1976) 45-58
76. Ratzenboeck E., Saria A., Kriechbaum N., and Zernig G. Reinforcing effects of MDMA ("ecstasy") in drug-naive and cocaine-trained rats. Pharmacology 62 (2001) 138-144
77. Rebec G.V. Behavioral electrophysiology of psychostimulants. Neuropsychopharmacology 31 (2006) 2341-2348
78. Rempel N.L., Callaway C.W., and Geyer M.A. Serotonin1B receptor activation mimics behavioral effects of presynaptic serotonin release. Neuropsychopharmacology 8 (1993) 201-211
79. Ricaurte G.A., Yuan J., and McCann U.D. (+/-)3,4-Methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: studies in animals. Neuropsychobiology 42 (2000) 5-10
80. Robinson T.E., Jurson P.A., Bennett J.A., and Bentgen K.M. Persistent sensitization of dopamine neurotransmission in ventral striatum (nucleus accumbens) produced by prior experience with (+)-amphetamine: a microdialysis study in freely moving rats. Brain Res 462 (1988) 211-222
81. Rothman R.B., and Baumann M.H. Balance between dopamine and serotonin release modulates behavioral effects of amphetamine-type drugs. Ann N Y Acad Sci 1074 (2006) 245-260
82. Rothman R.B., and Baumann M.H. Therapeutic and adverse actions of serotonin transporter substrates. Pharmacol Ther 95 (2002) 73-88
83. Rothman R.B., Baumann M.H., Dersch C.M., Romero D.V., Rice K.C., Carroll F.I., et al. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39 (2001) 32-41
84. Rothman R.B., Blough B.E., Woolverton W.L., Anderson K.G., Negus S.S., Mello N.K., et al. Development of a rationally designed, low abuse potential, biogenic amine releaser that suppresses cocaine self-administration. J Pharmacol Exp Ther 313 (2005) 1361-1369
85. Rothman R.B., Elmer G.I., Shippenberg T.S., Rea W., and Baumann M.H. Phentermine and fenfluramine. Preclinical studies in animal models of cocaine addiction. Ann N Y Acad Sci 844 (1998) 59-74
86. Schenk S., Gittings D., Johnstone M., and Daniela E. Development, maintenance and temporal pattern of self-administration maintained by ecstasy (MDMA) in rats. Psychopharmacology (Berl) 169 (2003) 21-27
87. Schmidt C.J., Levin J.A., and Lovenberg W. In vitro and in vivo neurochemical effects of methylenedioxymethamphetamine on striatal monoaminergic systems in the rat brain. Biochem Pharmacol 36 (1987) 747-755
88. Schmidt C.J., Sullivan C.K., and Fadayel G.M. Blockade of striatal 5-hydroxytryptamine2 receptors reduces the increase in extracellular concentrations of dopamine produced by the amphetamine analogue 3,4-methylenedioxymethamphetamine. J Neurochem 62 (1994) 1382-1389
89. Selken J., and Nichols D.E. Alpha1-adrenergic receptors mediate the locomotor response to systemic administration of (+/-)-3,4-methylenedioxymethamphetamine (MDMA) in rats. Pharmacol Biochem Behav 86 (2007) 622-630
90. Shankaran M., and Gudelsky G.A. A neurotoxic regimen of MDMA suppresses behavioral, thermal and neurochemical responses to subsequent MDMA administration. Psychopharmacology (Berl) 147 (1999) 66-72
91. Sharp T., Zetterstrom T., Ljungberg T., and Ungerstedt U. A direct comparison of amphetamine-induced behaviours and regional brain dopamine release in the rat using intracerebral dialysis. Brain Res 401 (1987) 322-330
92. Spanos L.J., and Yamamoto B.K. Acute and subchronic effects of methylenedioxymethamphetamine [(+/-)MDMA] on locomotion and serotonin syndrome behavior in the rat. Pharmacol Biochem Behav 32 (1989) 835-840
93. Swerdlow N.R., Vaccarino F.J., Amalric M., and Koob G.F. The neural substrates for the motor-activating properties of psychostimulants: a review of recent findings. Pharmacol Biochem Behav 25 (1986) 233-248
94. Tricklebank M.D., Forler C., and Fozard J.R. The involvement of subtypes of the 5-HT1 receptor and of catecholaminergic systems in the behavioural response to 8-hydroxy-2-(di-n-propylamino)tetralin in the rat. Eur J Pharmacol 106 (1984) 271-282
95. Trigo J.M., Renoir T., Lanfumey L., Hamon M., Lesch K.P., Robledo P., et al. 3,4-methylenedioxymethamphetamine self-administration is abolished in serotonin transporter knockout mice. Biol Psychiatry 62 (2007) 669-679
96. Tzschentke T.M., and Schmidt W.J. Functional relationship among medial prefrontal cortex, nucleus accumbens, and ventral tegmental area in locomotion and reward. Crit Rev Neurobiol 14 (2000) 131-142
97. Ungerstedt U. Stereotaxic mapping of the monoamine pathways in the rat brain. Acta Physiol Scand Suppl 367 (1971) 1-48
98. Verrico C.D., Miller G.M., and Madras B.K. MDMA (Ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment. Psychopharmacology (Berl) 189 (2007) 489-503
99. Yamamoto B.K., Nash J.F., and Gudelsky G.A. Modulation of methylenedioxymethamphetamine-induced striatal dopamine release by the interaction between serotonin and gamma-aminobutyric acid in the substantia nigra. J Pharmacol Exp Ther 273 (1995) 1063-1070
100. Yurek D.M., Hipkens S.B., Hebert M.A., Gash D.M., and Gerhardt G.A. Age-related decline in striatal dopamine release and motoric function in brown Norway/Fischer 344 hybrid rats. Brain Res 791 (1998) 246-256